Characterization of Impurities and Degradants in Protein Therapeutics by Mass Spectrometry

Characterization of Impurities and Degradants Using Mass Spectrometry

Volumn , Issue , 2011, Pages 391-426

  Tao, Li ^a   Ackerman, Michael ^a   Wu, Wei ^a   Liu, Peiran ^a   Russell, Reb ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Characterization and quantitative analysis of oxidation role in biopharmaceutical development; Impurity and degradant characterization in protein therapeutics by mass spectrometry protein based drugs, therapeutic targets; MS pivotal role, in biomolecule understanding component monitoring, biomolecules produced reproducibly, with variant amount

Indexed keywords

EID: 84886075277     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470921371.ch12     Document Type: Chapter

References (219)

1. Leader, B.; Baca, Q. J.; Golan, D. E. (2008), Protein therapeutics: A summary and pharmacological classification, Nat. Rev. Drug Discov. 7, 21-39.
2. Aggarwal, S. (2009), What's fueling the biotech engine-2008, Nat. Biotechnol. 27, 987-993
3. Tanaka, K.; Waki, H.; Ido, Y.; Akita, S.; Yoshida, Y.; Yoshida, T. (1988), Protein and polymer analyses up to m/z 100,000 by laser ionization time-of-flight mass spectrometry, Rapid Commun. Mass Spectrom. 2, 151-153.
4. Fenn, J. B.; Mann, M.; Meng, C. K.;Wong, S. F.; Whitehouse, C. M. (1989), Electrospray ionization for mass spectrometry of large biomolecules, Science 246, 64-71.
5. Glish, G. L.; Vachet, R. W. (2003), The basics of mass spectrometry in the twenty-first century, Nat. Rev. Drug Discov. 2, 140-150.
6. Kriwacki, R.; Reisdorph, N.; Siuzdak, G. (2004), Protein structure characterization with mass spectrometry, Spectroscopy 18, 37-47.
7. Wysocki, V. H.; Resing, K. A.; Zhang, Q.; Cheng, G. (2005), Mass spectrometry of peptides and proteins, Methods 35, 211-222.
8. Domon, B.; Aebersold, R. (2006), Mass spectrometry and protein analysis, Science 312, 212-217.
9. Chen, G.; Pramanik, B. N. (2009), Application of LC/MS to proteomics studies: Current status and future prospects, Drug Discov. Today 14, 465-471.
10. Chen, G., Pramanik, B. N. (2008), LC-MS for protein characterization: Current capabilities and future trends, Expert Rev. Proteom. 5, 435-444.
11. Janiszewski, J. S.; Liston, T. E.; Cole, M. J. (2008), Perspectives on bioanalytical mass spectrometry and automation in drug discovery. Curr. Drug Metab. 9, 986-994.
12. Annis, D. A.; Nickbarg, E.; Yang, X.; Ziebell, M. R.; Whitehurst, C. E. (2007), Affinity selection-mass spectrometry screening techniques for small molecule drug discovery, Curr. Opin. Chem. Biol. 11, 518-526.
13. Servais, A.-C.; Crommen, J.; Fillet, M. (2006), Capillary electrophoresis-mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery, Electrophoresis 27, 2616-2629.
14. Deng, G.; Sanyal, G. (2006), Applications of mass spectrometry in early stages of target based drug discovery, J. Pharm. Biomed. Anal. 40, 528-538.
15. Zhang, J.; McCombie, G.; Guenat, C.; Knochenmuss, R. (2005), FT-ICR mass spectrometry in the drug discovery process, Drug Discov. Today 10, 635-642.
16. Flook, P. K.; Yan, L.; Szalma, S. (2003), Target validation through high throughput proteomics analysis, Drug Discov. Today (TARGETS) 2, 217-223.
17. Valle, R. P. C.; Jendoubi, M. (2003), Antibody-based technologies for target discovery, Curr. Opin. Drug Discov. Devel. 6, 197-203.
18. Ryan, T. E.; Patterson, S. D. (2002), Proteomics: Drug target discovery on an industrial scale. Trends Biotechnol. 20, S45-51.
19. Weng, Z.; DeLisi, C. (2002), Protein therapeutics: Promises and challenges for the 21st century, Trends Biotechnol. 20, 29-35.
20. Veenstra, T. D. (2006), Proteomic approaches in drug discovery, Drug Discov. Today (Technol.) 3, 433-440.
21. Papac, D. I.; Shahrokh, Z. (2001), Mass spectrometry innovations in drug discovery and development, Pharm. Res. 18, 131-145.
22. John, H.; Walden, M.; SchÄfer, S.; Genz, S.; Forssmann, W.-G. (2004), Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography- mass spectrometry, Anal. Bioanal. Chem. 378, 883-897.
23. Ovsyannikova, I. G.; Johnson, K. L.; Bergen, H. R., III; Poland, G. A. (2007), Mass spectrometry and peptide-based vaccine development, Clin. Pharmacol. Ther. 82, 644- 652.
24. Azad, N. S.; Rasool, N.; Annunziata, C. M.; Minasian, L.; Whiteley, G.; Kohn, E. C. (2006), Proteomics in clinical trials and practice: Present uses and future promise, Molec. Cell. Proteom. 5, 1819-1829.
25. Daugherty, A. L.; Mrsny, R. J. (2006), Formulation and delivery issues for monoclonal antibody therapeutics, Adv. Drug Deliv. Rev. 58, 686-706.
26. Baumann, A. (2006), Early development of therapeutic biologics-Pharmacokinetics, Curr. Drug Metab. 7, 15-21.
27. Hicks, L. M.; Mazur, M. T.; Miller, L. M.; Dorrestein, P. C.; Schnarr, N. A.; Khosla, C.; Kelleher, N. L. (2006), Investigating nonribosomal peptide and polyketide biosynthesis by direct detection of intermediates on >70 kDa polypeptides by using fourier-transform mass spectrometry, ChemBioChem. 7, 904-907.
28. Horn, D. M.; Zubarev, R. A.; McLafferty, F.W. (2000), Automated de novo sequencing of proteins by tandem high-resolution mass spectrometry, Proc. Natl. Acad. Sci. USA 97, 10313-10317.
29. Rosenfeld J.; Capdevielle, J.; Guillemot, J. C.; Ferrara, P. (1992), In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis, Anal. Biochem. 203, 173-179.
30. Hellman, U.;Wernstedt, C.; Góñez, J.; Heldin, C. H. (1995), Improvement of an "In-Gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing, Anal. Biochem. 224, 451-455.
31. Shevchenko A.,Wilm M., Vorm O., Mann M. (1996), Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels, Anal. Chem. 68, 850-858.
32. Aebersold, R.; Mann, M. (2003), Mass spectrometry-based proteomics, Nature, 422, 198-207.
33. Liebers, V.; Raulf-Heimsoth, M.; Bróning, T. (2008), Health effects due to endotoxin inhalation, Arch. Toxicol. 82, 203-210.
34. Liebers, V.; Bróning, T.; Raulf-Heimsoth, M. (2006), Occupational endotoxin-exposure and possible health effects on humans, Am. J. Industr. Med. 49, 474-491.
35. Bryans, T. D.; Braithwaite, C.; Broad, J.; Cooper, J. F.; Darnell, K. R.; Hitchins, V. M.; Karren, A. J.; Lee, P. S. (2004), Bacterial endotoxin testing: A report on the methods, background, data, and regulatory history of extraction recovery efficiency. Biomed. Instrum. Technol. 38, 73-78.
36. Brandenburg, K.; Howe, J.; Gutsman, T.; Garidel, P. (2009), The expression of endotoxic activity in the Limulus test as compared to cytokine production in immune cells, Curr. Med. Chem. 16, 2653-2660.
37. Ding, J. L.; Ho, B. (2001), A new era in pyrogen testing, Trends Biotechnol. 19, 277-281.
38. Bolger, R.; Lenoch, F.; Allen, E.; Meiklejohn, B.; Burke, T. (1997), Fluorescent dye assay for detection of DNA in recombinant protein products, BioTechniques 23, 532-537.
39. Riggin, A.; Luu, V. T.; Lobdell, J. K.; Wind, M. K. (1997), A non-isotopic probehybridization assay for residualDNAin biopharmaceuticals, J. Pharm. Biomed. Anal. 16, 561-572.
40. Ji, X.; Lee, K.; DiPaolo, B. (2002), High-sensitivity hybridization assay for quantitation of residual E. coli DNA, BioTechniques 32, 1162-1167.
41. Konrad, M. (1989), Immunogenecity of proteins administered to humans for therapeutic purposes, Trends Biotechnol. 7, 175-179.
42. Eaton, L. C. (1995), Host cell contaminant protein assay development for recombinant biopharmaceuticals, J. Chromatogr. A 705, 105-114.
43. Ghobrial, I. A.; Wong, D. T.; Sharma, B. G. (1997), An immuno-ligand assay for the detection and quantitation of contaminating proteins in recombinant human erythropoietin (r-HuEPO), Pharm. Technol. 21, 48-56.
44. Chen, A. B.; Championsmith, A. A.; Blanchard, J.; Gorrell, J.; Niepelt, B. A.; Federici, M. M.; Formento, J.; Sinicropi, D. V. (1992), Quantitation of E. coli protein impurities in recombinant human interferon-g, Appl. Biochem. Biotechnol. 36, 137-152.
45. Whitmire, M. L.; Eaton, L. C. (1997), An immunoligand assay for quantitation of process specific Escherichia coli host cell contaminant proteins in a recombinant bovine somatotropin, J. Immunoassay 18, 49-65.
46. Dagouassat, N.; Haeuw, J.-F.; Robillard, V.; Damien, F.; Libon, C.; CorvaÏa, N.; Lawny, F.; Nguyen, T. N.; Bonnefoy, J.-Y.; Beck, A. (2001), Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus, J. Immunol. Meth. 251, 151-159.
47. Fowler, J. D.; Brown, J. A.; Kvaratskhelia, M.; Suo, Z. (2009), Probing conformational changes of human DNA polymerase l using mass spectrometry-based protein footprinting. J. Molec. Biol. 390, 368-379.
48. Kvaratskhelia M.; Miller, J. T.; Budihas, S. R.; Pannell, L. K.; Le Grice, S. F. J. (2002), Identification of specific HIV-1 reverse transcriptase contacts to the viral RNA:tRNA complex by mass spectrometry and a primary amine selective reagent, Proc. Nat. Acad. Sci. USA 99, 15988-15993.
49. Wood, T. D.; Guan, Z.; Borders, C. L., Jr.; Chen, L. H.; Kenyon, G. L.; Mclafferty, F.W. (1998), Creatine kinase: Essential arginine residues at the nucleotide binding site identified by chemical modification and high-resolution tandem mass spectrometry, Proc. Nat. Acad. Sci. USA 95, 3362-3365.
50. Philo, J. S.; Arakawa, T. (2009), Mechanisms of protein aggregation, Curr. Pharm. Biotechnol. 10, 348-351.
51. Chi, E. Y.; Krishnan, S.; Randolph, T. W.; Carpenter, J. F. (2003), Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation, Pharm. Res. 20, 1325-1336.
52. Philo, J. S. (2009), A critical review of methods for size characterization of nonparticulate protein aggregates, Curr. Pharm. Biotechnol. 10, 359-372.
53. Philo, J. S. (2006), Is any measurement method optimal for all aggregate sizes and types? AAPS (Am. Assoc. Pharmceutical. Scientists) J. 8, 564-571.
54. Cao, S.; Pollastrini, J.; Jiang, Y. (2009), Separation and characterization of protein aggregates and particles by field flow fractionation, Curr. Pharm. Biotechnol. 10, 382-390.
55. Kendrick, B. S.; Kerwin, B. A.; Chang, B. S.; Philo, J. S. (2001), Online size-exclusion high-performance liquid chromatography light scattering and differential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states, Anal. Biochem. 299, 136-146.
56. Philo, J. S. (2001), Ultracentrifugation, BioPharm. 14, 52-54.
57. Harris, R. J.; Kabakoff, B.; Macchi, F. D.; Shen, F. J.; Kwong, M.; Andya, J. D.; Shire, S. J.; Bjork, N.; Totpal, K.; Chen, A. B. (2001), Identification of multiple sources of charge heterogeneity in a recombinant antibody, J. Chromatogr. B (Biomed. Sci. Appl.) 752, 233-245.
58. Di Donato, A.; Ciardiello, M. A.; De Nigris, M.; Piccoli, R.; Mazzarella, L.; D'Alessio, G. (1993), Selective deamidation of ribonuclease A. Isolation and characterization of the resulting isoaspartyl and aspartyl derivatives, J. Biol. Chem. 268, 4745-4751.
59. Gupta, R.; Srivastava, O. P. (2004), Deamidation affects structural and functional properties of human aA-crystallin and its oligomerization with a B-crystallin, J. Biol. Chem. 279, 44258-44269.
60. Cacia, J.; Keck, R.; Presta, L. G.; Frenz, J. (1996), Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity, Biochemistry 35, 1897-1903.
61. Harris, R. J.; Kabakoff, B.; Macchi, F. D.; Shen, F. J.; Kwong, M.; Andya, J. D.; Shire, S. J.; Bjork, N.; Totpal, K.; Chen, A. B. (2001), Identification of multiple sources of charge heterogeneity in a recombinant antibody, J. Chromatogr. B (Biomed. Sci. Appl.) 752, 233-245.
62. Paborji, M.; Pochopin, N. L.; Coppola, W. P.; Bogardus, J. B. (1994), Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody, Pharm. Res. 11, 764-771.
63. Geiger, T.; Clarke, S. (1987), Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation, J. Biol. Chem., 262, 785-794.
64. Kroon, D. J.; Baldwin-Ferro, A.; Lalan, P. (1992), Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping, Pharm. Res., 9, 1386-1393.
65. Hsu, Y.-R.; Chang,W.-C.; Mendiaz, E. A.; Hara, S.; Chow, D. T.; Mann, M. B.; Langley, K. E.; Lu, H. S. (1998), Selective deamidation of recombinant human stem cell factor during in vitro aging: Isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers, Biochemistry 37, 2251-2262.
66. Tsai, P. K.; Bruner,M.W.; Irwin, J. I.; Ip, C. C.Y.; Oliver, C. N.; Nelson, R.W.;Volkin, D. B.; Middaugh, C. R. (1993), Origin of the isoelectric heterogeneity of monoclonal immunoglobulin h1B4, Pharm. Res., 10, 1580-1586.
67. Noguchi, S.; Miyawaki, K.; Satow, Y. (1998), Succinimide and isoaspartate residues in the crystal structures of hen egg-white lysozyme complexed with tri-N-acetylchitotriose, J. Molec. Biol. 278, 231-238.
68. Huang, L.; Lu, J.; Wroblewski, V. J.; Beals, J. M.; Riggin, R. M. (2005), In vivo deamidation characterization of monoclonal antibody by LC/MS/MS, Anal. Chem. 77, 1432-1439.
69. Paul, S. R.; Bennett, F.; Calvetti, J. A.; Kelleher, K.; Wood, C. R.; O'Hara, R. M., Jr.; Leary, A. C.; Sibley, B.; Clark, S. C.; Williams, D. A.; Yang, Y.-C. (1990), Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine, Proc. Nat. Acad. Sci. USA 87, 7512-7516.
70. Tyler-Cross, R.; Schirch, V. (1991), Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides, J. Biol. Chem., 266, 22549-22556.
71. Solstad, T.; Carvalho, R. N.; Andersen, O. A.; Waidelich, D.; Flatmark, T. (2003), Deamidation of labile asparagine residues in the autoregulatory sequence of human phenylalanine hydroxylase: Structural and functional implications, Eur. J. Biochem. 270, 929-938.
72. Paborji, M.; Pochopin, N. L.; Coppola, W. P.; Bogardus, J. B. (1994), Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody, Pharm. Res. 11, 764-771.
73. Rao, P. E.; Kroon, D. J. (1993), Orthoclone OKT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody, Pharm. Biotechnol. 5, 135- 158.
74. Liu, Y. D.; van Enk, J. Z.; Flynn, G. C. (2009), Human antibody Fc deamidation in vivo, Biologicals 37, 313-322.
75. Hsu, Y.-R.; Chang,W.-C.; Mendiaz, E. A.; Hara, S.; Chow, D. T.; Mann, M. B.; Langley, K. E.; Lu, H. S. (1998), Selective deamidation of recombinant human stem cell factor during in vitro aging: Isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers, Biochemistry 37, 2251-2262.
76. Tsai, P. K.; Bruner,M.W.; Irwin, J. I.; Ip, C. C.Y.; Oliver, C. N.; Nelson, R.W.;Volkin, D. B.; Middaugh, C. R. (1993), Origin of the isoelectric heterogeneity of monoclonal immunoglobulin h1B4, Pharm. Res. 10, 1580-1586.
77. Yan, B.; Steen, S.; Hambly, D.; Valliere-Douglass, J.; Vanden Bos, T.; Smallwood, S.; Yates, Z.; Arroll, T.; Han, Y.; Gadgil, H.; Latypov, R. F.; Wallace, A.; et al. (2009), Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain, J. Pharm. Sci. 98, 3509-3521.
78. Vlasak, J.; Bussat, M. C.;Wang, S.;Wagner-Rousset, E.; Schaefer, M.; Klinguer-Hamour, C.; Kirchmeier, M.; CorvaÏa, N.; Ionescu, R.; Beck, A. (2009), Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody, Anal. Biochem. 392, 145-154.
79. Friedman, A. R.; Ichhpurani, A. K.; Brown, D. M.; Hillman, R. M.; Krabill, L. F.; Martin, R. A.; Zurcher-Neely, H. A.; Guido, D. M. (1991), Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizers, Int. J. Peptide Protein Res. 37, 14-20.
80. Harris, R. J.; Kabakoff, B.; Macchi, F. D.; Shen, F. J.; Kwong, M.; Andya, J. D.; Shire, S. J.; Bjork, N.; Totpal, K.; Chen, A. B. (2001), Identification of multiple sources of charge heterogeneity in a recombinant antibody, J. Chromatogr. B (Biomed. Sci. Appl.) 752, 233-245.
81. Aswad, D. W.; Paranandi, M. V.; Schurter, B. T. (2000), Isoaspartate in peptides and proteins: Formation, significance, and analysis, J. Pharm. Biomed. Anal. 21, 1129-1136.
82. Paul, S. R.; Bennett, F.; Calvetti, J. A.; Kelleher, K.; Wood, C. R.; O'Hara, R. M., Jr.; Leary, A. C.; Sibley, B.; Clark, S. C.; Williams, D. A.; Yang, Y.-C. (1990), Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine, Proc. Nat. Acad. Sci. USA, 87, 7512-7516.
83. Tyler-Cross, R.; Schirch, V. (1991), Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides, J. Biol. Chem., 266, 22549-22556.
84. Huang, H. Z.; Nichols, A.; Liu, D. (2009), Direct identification and quantification of aspartyl succinimide in an IgG2 mAb by RapiGest assisted digestion, Anal. Chem., 81, 1686-1692.
85. Bischoff, R.; Lepage, P.; Jaquinod, M.; Cauet, G.; Acker-Klein, M.; Clesse, D.; Laporte, M.; Bayol, A.; Van Dorsselaer, A.; Roitsch, C. (1993), Sequence-specific deamidation: Isolation and biochemical characterization of succinimide intermediates of recombinant hirudin, Biochemistry 32, 725-734.
86. Gotte, G.; Libonati, M.; Laurents, D. V. (2003), Glycosylation and specific deamidation of ribonuclease B affect the formation of three-dimensional domain-swapped oligomers. J. Biol. Chem., 278, 46241-46251.
87. Zhang,W.; Czupryn, M. J. (2003), Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms, J. Pharm. Biomed. Anal. 30, 1479-1490.
88. Lindner, H.; Sarg, B.; Grunicke, H.; Helliger, W. (1999), Age-dependent deamidation of H1°histones in chromatin of mammalian tissues, J. Cancer Res. Clin. Oncol. 125, 182-186.
89. Wakankar, A. A.; Borchardt, R. T.; Eigenbrot, C.; Shia, S.;Wang, Y. J.; Shire, S. J.; Liu, J. L. (2007), Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies, Biochemistry 46, 1534-1544.
90. Johnson, B. A.; Aswad, D. W. (1991), Optimal conditions for the use of protein Lisoaspartyl methyltransferase in assessing the isoaspartate content of peptides and proteins, Anal. Biochem. 192, 384-391.
91. Johnson, B. A.; Aswad, D. W. (1993), Kinetic properties of bovine brain protein Lisoaspartyl methyltransferase determined using a synthetic isoaspartyl peptide substrate, Neurochem. Res. 18, 87-94.
92. Schmid, D. G.; Von der Mulbe, F.; Fleckenstein, B.; Weinschenk, T.; Jung, G. (2001), Broadband detection electrospray ionization fourier transform ion cyclotron resonance mass spectrometry to reveal enzymatically and chemically induced deamidation reactions within peptides, Anal. Chem. 73, 6008-6013.
93. Zabrouskov, V.; Han, X.;Welker, E.; Zhai, H.; Lin, C.; VanWijk, K. J.; Scheraga, H. A.; McLafferty, F. W. (2006), Stepwise deamidation of ribonuclease A at five sites determined by top down mass spectrometry, Biochemistry 45, 987-992.
94. Robinson, N. E.; Zabrouskov, V.; Zhang, J.; Lampi, K. J.; Robinson, A. B. (2006), Measurement of deamidation of intact proteins by isotopic envelope and mass defect with ion cyclotron resonance Fourier transform mass spectrometry, Rapid Commun. Mass Spectrom. 20, 3535-3541.
95. O'Connor, P. B.; Cournoyer, J. J.; Pitteri, S. J.; Chrisman, P. A.; McLuckey, S. A. (2006), Differentiation of aspartic and isoaspartic acids using electron transfer dissociation, J. Am. Soc. Mass Spectrom. 17, 15-19.
96. Cournoyer, J. J.; Pittman, J. L.; Ivleva, V. B.; Fallows, E.; Waskell, L.; Costello, C. E.; O'Connor, P. B. (2005), Deamidation: Differentiation of aspartyl from isoaspartyl products in peptides by electron capture dissociation, Protein Sci. 14, 452-463.
97. Chelius, D.; Render, D. S.; Bondarenko, P. V. (2005), Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies, Anal. Chem. 77, 6004-6011.
98. Gaza-Bulseco, G.; Liu, H. (2008), Fragmentation of a recombinant monoclonal antibody at various pH, Pharm. Res. 25, 1881-1890.
99. Brennan, T.V.; Clarke, S. (1995), Effect of adjacent histidine and cysteine residues on the spontaneous degradation of asparaginyl- and aspartyl-containing peptides, Int. J. Peptide Protein Res. 45, 547-553.
100. Robinson, N. E.; Robinson, Z. W.; Robinson, B. R.; Robinson, A. L.; Robinson, J. A.; Robinson, M. L.; Robinson, A. B. (2004), Structure-dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides, J. Peptide Res. 63, 426-436.
101. Patel, K.; Borchardt, R. T. (1990), Chemical pathways of peptide degradation. III. effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides, Pharm. Res. 7, 787-793.
102. Kosky, A. A.; Razzaq, U. O.; Treuheit, M. J.; Brems, D. N. (1999), The effects of alphahelix on the stability of Asn residues: Deamidation rates in peptides of varying helicity, Protein Sci. 8, 2519-2523.
103. Wearne, S. J.; Creighton, T. E. (1989), Effect of protein conformation on rate of deamidation: Ribonuclease A, Proteins Struct. Funct. Genet. 5, 8-12.
104. Sinha, S.; Zhang, L.; Duan, S.; Williams, T. D.; Vlasak, J.; Ionescu, R.; Topp, E. M. (2009), Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody, Protein Sci. 18, 1573-1584.
105. Liu, H.; Gaza-Bulseco, G.; Sun, J. (2006), Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature, J. Chromatogr. B (Anal. Technol. Biomed. Life Sci.) 837, 35-43.
106. Liu, H.; Gaza-Bulseco, G.; Chumsae, C. (2008), Glutamine deamidation of a recombinant monoclonal antibody, Rapid Commun. Mass Spectrom. 22, 4081-4088.
107. Wright, H. T. (1991), Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins, Crit. Rev. Biochem. Molec. Biol. 26, 1-52.
108. Oliyai, C.; Borchardt, R. T. (1993), Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide, Pharm. Res. 10, 95-102.
109. Wakankar, A. A.; Borchardt, R. T. (2006), Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization, J. Pharm. Sci. 95, 2321-2336.
110. Brennan, T. V.; Clarke, S. (1993), Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric, Protein Sci. 2, 331-338.
111. Zhang, W.; Czupryn, M. J.; Boyle, P. T., Jr.; Amari, J. (2002), Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin- 11, Pharm. Res. 19, 1223-1231.
112. Clarke, S. (1987), Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins, Int. J. Peptide Protein Res. 30, 808-821.
113. Violand, B. N.; Schlittler, M. R.; Toren, P. C.; Siegel, N. R. (1990), Formation of isoaspartate 99 in bovine and porcine somatotropins, J. Protein Chem. 9, 109-117.
114. Catak, S.; Monard, G.; Aviyente, V.; Ruiz-López, M. F. (2008), Computational study on nonenzymatic peptide bond cleavage at asparagine and apartic acid, J. Phys. Chem.A112, 8752-8761.
115. Joshi, A. B.; Rus, E.; Kirsch, L. E. (2000), The degradation pathways of glucagon in acidic solutions, Int. J. Pharm. 203, 115-125.
116. Joshi, A. B.; Sawai, M.;Kearney,W. R.; Kirsch, L. E. (2005), Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon, J. Pharm. Sci. 94, 1912-1927.
117. Pisskiewicz, D.; Michael L.; Smith, E. L. (1970), Anomalous cleavage of aspartyl-proline peptide bonds during amino acid sequence determination, Biochem. Biophys. Res. Commun. 40, 1173-1178.
118. Gerschler, J. J.; Wier, K. A.; Hansen, D. E. (2007), Amide bond cleavage: Acceleration due to a 1,3-diaxial interaction with a carboxylic acid, J. Org. Chem. 72, 654-657.
119. Landon, M. (1977), Cleavage at aspartyl-prolyl bonds, Meth. Enzymol. 47, 145-149.
120. Marcus, F. (1985), Preferential cleavage at aspartyl-prolyl peptide bonds in dilute acid, Int. J. Peptide Protein Res. 25, 542-546.
121. Voorter,C.E.M.; De Haard-Hoekman,W. A.;Van Den Oetelaar, P. J. M.; Bloemendal, H.; De Jong,W.W. (1988), Spontaneous peptide bond cleavage in aging a-crystallin through a succinimide intermediate, J. Biol. Chem. 263, 19020-19023.
122. Cordoba, A. J.; Shyong, B.-J.; Breen, D.; Harris, R. J. (2005), Non-enzymatic hinge region fragmentation of antibodies in solution, J. Chromatogr. B (Anal. Technol. Biomed. Life Sci.) 818, 115-121.
123. Cohen, S. L.; Price, C.; Vlasak, J. (2007), b-Elimination and peptide bond hydrolysis: Two distinct mechanisms of human IgG1 hinge fragmentation upon storage, J. Am. Chem. Soc. 129, 6976-6977.
124. Liu, H.; Gaza-Bulseco, G.; Lundell, E. (2008), Assessment of antibody fragmentation by reversed-phase liquid chromatography and mass spectrometry, J. Chromatogr. B (Anal. Technol. Biomed. Life Sci.) 876, 13-23.
125. Jiskoot,W.; Beuvery, E. C.; de Koning, A. M.; Herron, J. N.; Crommelin, D. J. A. (1990), Pharm. Res. 7, 1234-1241.
126. Alexander, A. J.; Hughes, D. E. (1995), Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ ionization mass spectrometry, Anal Chem. 67, 3626-3632.
127. Smith, M. A.; Easton, M.; Everett, P.;Lewis, G.; Payne, M.; Riveros-Moreno,V.; Allen, G. (1996), Specific cleavage of immunoglobulin G by copper ions, Int. J. Peptide Protein Res. 48, 48-55.
128. Davies, K. J. (1987), Protein damage and degradation by oxygen radicals. I. General aspects, J. Biol. Chem., 262, 9895-9901.
129. Davies, K. J.; Delsignore, M. E.; Lin, S. W. (1987), Protein damage and degradation by oxygen radicals. II. Modification of amino acids, J. Biol. Chem., 262, 9902-9907.
130. Dean, R. T.; Fu, S.; Stocker, R.; Davies, M. J. (1997), Biochemistry and pathology of radical-mediated protein oxidation, Biochem. J. 324, 1-18.
131. Garrison,W. M. (1987), Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins, Chem. Rev. 87, 381-398.
132. Cecarini, V.; Gee, J.; Fioretti, E.; Amici, M.; Angeletti, M.; Eleuteri, A. M.; Keller, J. N. (2007), Protein oxidation and cellular homeostasis: Emphasis on metabolism, Biochim. Biophys. Acta (Molec. Cell Res.) 1773, 93-104.
133. Grune, T.; Klotz, L.-O.; Gieche, J.; Rudeck, M.; Sies, H. (2001), Protein oxidation and proteolysis by the nonradical oxidants singlet oxygen or peroxynitrite, Free Radical Biol. Med. 30, 1243-1253.
134. Hawkins, C. L.; Pattison, D. I.; Davies, M. J. (2003), Hypochlorite-induced oxidation of amino acids, peptides and proteins, Amino Acids 25, 259-274.
135. Stadtman, E. R. (1990), Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences, Free Radical Biol. Med. 9, 315-325.
136. Stadtman, E. R.; Levine, R. L. (2000), Protein oxidation, Ann. NY Acad. Sci. 899, 191- 208.
137. Stadtman, E. R.;Levine, R. L. (2003), Free radical-mediated oxidation of free amino acids and amino acid residues in proteins, Amino Acids 25, 207-218.
138. Shacter, E. (2000), Protein oxidative damage, Meth. Enzymol. 319, 428-436.
139. Berlett, B. S.; Stadtman, E. R. (1997), Protein oxidation in aging, disease, and oxidative stress, J. Biol. Chem. 272, 20313-20316.
140. Stadtman, E. R.; Berlett, B. S. (1998), Reactive oxygen-mediated protein oxidation in aging and disease, Drug Metab. Rev. 30, 225-243.
141. Stadtman, E. R.; Oliver, C. N. (1991), Metal-catalyzed oxidation of proteins: Physiological consequences, J. Biol. Chem. 266, 2005-2008.
142. Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.;Witztum, J. L. (1989), Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity, N. Engl. J. Med. 320, 915-924.
143. Levine, R. L.; Berlett, B. S.; Moskovitz, J.; Mosoni, L.; Stadtman, E. R. (1999), Methionine residues may protect proteins from critical oxidative damage, Mech. Ageing Devel. 107, 323-332.
144. Levine, R. L.; Wehr, N.; Williams, J. A.; Stadtman, E. R.; Shacter, E. (2000), Determination of carbonyl groups in oxidized proteins, Meth. Molec. Biol. 99, 15-24.
145. Stadtman, E. R.; Moskovitz, J.; Levine, R. L. (2003), Oxidation of methionine residues of proteins: Biological consequences, Antioxidants Redox Signal. 5, 577-582.
146. Manning, M. C.; Patel, K.; Borchardt, R. T. (1989), Stability of protein pharmaceuticals, Pharm. Res. 6, 903-917.
147. Wasylaschuk, W. R.; Harmon, P. A.; Wagner, G.; Harman, A. B.; Templeton, A. C.; Xu, H.; Reed, R. A. (2007), Evaluation of hydroperoxides in common pharmaceutical excipients, J. Pharm. Sci. 96, 106-116.
148. Huang, T.; Garceau, M. E.; Gao, P. (2003), Liquid chromatographic determination of residual hydrogen peroxide in pharmaceutical excipients using platinum and wired enzyme electrodes, J. Pharm. Biomed. Anal. 31, 1203-1210.
149. Hawkins, C. L.; Davies, M. J. (1998), EPR studies on the selectivity of hydroxyl radical attack on amino acids and peptides, J. Chem. Soc. Perkin Trans. 2, 2617-2622.
150. Hawkins, C. L.; Davies, M. J. (2001), Generation and propagation of radical reactions on proteins, Biochim. Biophys. Acta (Bioenergetics) 1504, 196-219.
151. Davies, M. J.; Fu, S.;Wang, H.; Dean, R. T. (1999), Stable markers of oxidant damage to proteins and their application in the study of human disease, Free Radical Biol. Med. 27, 1151-1163.
152. Eaton, P. (2006), Protein thiol oxidation in health and disease: Techniques for measuring disulfides and related modifications in complex protein mixtures, Free Radical Biol. Med. 40, 1889-1899.
153. Reddie, K. G.; Carroll, K. S. (2008), Expanding the functional diversity of proteins through cysteine oxidation, Curr. Opin. Chem. Biol. 12, 746-754.
154. Krishnamurthy, R.; Manning, M. C. (2002), The stability factor: Importance in formulation development, Curr. Pharm. Biotechnol. 3, 361-371.
155. Shetty, V.; Spellman, D. S.; Neubert, T. A. (2007), Characterization by tandem mass spectrometry of stable cysteine sulfenic acid in a cysteine switch peptide of matrix metalloproteinases, J. Am. Soc. Mass Spectrom. 18, 1544-1551.
156. Wu, J.; Watson, J. T. (1997), A novel methodology for assignment of disulfide bond pairings in proteins, Protein Sci. 6, 391-398.
157. Xiang, T.; Chumsae, C.; Liu, H. (2009), Localization and quantitation of free sulfhydryl in recombinant monoclonal antibodies by differential labeling with 12C and 13C iodoacetic acid and LC-MS analysis, Anal. Chem. 81, 8101-8108.
158. Ji, J. A.; Zhang, B.; Cheng,W.;Wang, Y. J. (2009), Methionine, tryptophan, and histidine oxidation in a model protein, PTH: Mechanisms and stabilization, J. Pharm. Sci. 98, 4485-4500.
159. Teh, L. C.; Murphy, L. J.; Huq, N. L.; Surus, A. S.; Friesen, H. G.; Lazarus, L.; Chapman, G. E. (1987), Methionine oxidation in human growth hormone and human chorionic somatomammotropin. Effects on receptor binding and biological activities, J. Biol. Chem. 262, 6472-6477.
160. Shen, J. F.; Kwong, Y. M.; Keck, G. R.; Harris, J. R. (1996), The application of tert- Butylhydroperoxide oxidization to study sites of potential methionine oxidization in a recombinant antibody, in Marshak, D. R., ed., Techniques in Protein Chemistry, Academic Press, New York, Vol. VII, pp. 275-284.
161. Lam, X. M.; Yang, J. Y.; Cleland, J. L. (1997), Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2, J. Pharm. Sci. 86, 1250-1255.
162. Chumsae, C.; Gaza-Bulseco, G.; Sun, J.; Liu, H. (2007), Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody, J. Chromatogr. B (Anal. Technol. Biomed. Life Sci.) 850, 285-294.
163. Hsu, Y.-R.; Narhi, L. O.; Spahr, C.; Langley, K. E.; Lu, H. S. (1996), In vitro methionine oxidation of Escherichia coli-derived human stem cell factor: Effects on the molecular structure, biological activity, and dimerization, Protein Sci. 5, 1165-1173.
164. Labrenz, S. R.; Calmann, M. A.; Heavner, G. A.; Tolman, G. (2008), The oxidation of methionine-54 of epoetinum alfa does not affect molecular structure or stability, but does decrease biological activity, PDA J. Pharm. Sci. Technol. 62, 211-223.
165. Caldwell, P.; Luk, D. C.; Weissbach, H.; Brot, N. (1978), Oxidation of the methionine residues of Escherichia coli ribosomal protein L12 decreases the protein's biological activity, Proc. Nat. Acad. Sci. USA 75, 5349-5352.
166. Shechter, Y.; Burstein, Y.; Gertler, A. (1977), Effect of oxidation of methionine residues in chicken ovoinhibitor on its inhibitory activities against trypsin, chymotrypsin, and elastase, Biochemistry 16, 992-997.
167. Neumann, N. P.; Moore, S.; Stein,W. H. (1962), Modification of the methionine residues in ribonuclease, Biochemistry 1, 68-75.
168. Kassell, B. (1964), The basic trypsin inhibitor of bovine pancreas. II. Alteration of the methionine residue, Biochemistry 3, 152-155.
169. Van Patten, S. M.; Hanson, E.; Bernasconi, R.; Zhang, K.; Manavalan, P.; Cole, E. S.; McPherson, J. M.; Edmunds, T. (1999), Oxidation of methionine residues in antithrombin: Effects on biological activity and heparin binding, J. Biol. Chem. 274, 10268-10276.
170. Brennan, L. A.; Lee, W.; Giblin, F. J.; David, L. L.; Kantorow, M. (2009), Methionine sulfoxide reductase A (MsrA) restores a-crystallin chaperone activity lost upon methionine oxidation, Biochim. Biophys. Acta (General Subjects) 1790, 1665-1672.
171. Jenkins, N. (2007), Modification of therapeutic proteins: Challenges and prospects, Cytotechnology 53, 121-125.
172. Houde, D.; Kauppinen, P.; Mhatre, R.; Lyubarskaya, Y. (2006), Determination of protein oxidation by mass spectrometry and method transfer to quality control, J. Chromatogr. A 1123, 189-198.
173. SchÖneich, C. (2000), Mechanisms of metal-catalyzed oxidation of histidine to 2-oxohistidine in peptides and proteins, J. Pharm. Biomed. Anal. 21, 1093-1097.
174. Matamoros Fernandez, L. E.; Kalume, D. E.; Calvo, L.; Fernandez Mallo, M.; Vallin, A.; Roepstorff, P. (2001), Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography, J Chromatogr. B (Biomed. Sci. Appl.) 752, 247-261.
175. Yang, J.;Wang, S.; Liu, J.; Raghani, A. (2007), Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography, J. Chromatogr. A 1156, 174-182.
176. Wei, Z.; Feng, J.; Lin, H.Y.; Mullapudi, S.; Bishop, E.; Tous, G. I.; Casas-Finet, J.; Hakki, F.; Strouse, R.; Schenerman, M. A. (2007), Identification of a single tryptophanresidue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus, Anal. Chem. 79, 2797-2805.
177. Hashimoto, K.; Goto, S.; Kawano, S.; Aoki-Kinoshita, K. F.; Ueda, N.; Hamajima, M.; Kawasaki, T.; Kanehisa, M. (2006), KEGG as a glycome informatics resource, Glycobiology 16, 63R-70R.
178. Hossler, P.; Khattak, S. F.; Li, Z. J. (2009), Optimal and consistent protein glycosylation in mammalian cell culture, Glycobiology 19, 936-949.
179. Lis, H.; Sharon, N. (1993), Protein glycosylation. Structural and functional aspects, Eur. J. Biochem. 218, 1-27.
180. Sola, R. J.; Griebenow, K. (2009), Effects of glycosylate on the stability of protein pharmaceuticals, J. Pharm. Sci. 98, 1223-1245.
181. Coloma, M. J.; Trinh, R. K.; Martinez, A. R.; Morrison, S. L. (1999), Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1!6) dextran antibody, J. Immunol. 162, 2162-2170.
182. Sethuraman, N.; Stadheim, T. A. (2006), Challenges in therapeutic glycoprotein production, Curr. Opin. Biotechnol. 17, 341-346.
183. Noguchi, A.; Mukuria, C. J.; Suzuki, E.; Naiki, M. (1995), Immunogenicity of Nglycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells, J. Biochem. 117, 59-62.
184. Jefferis, R. (2005), Glycosylation of recombinant antibody therapeutics, Biotechnol, Progress 21, 11-16.
185. Gala, F. A.; Morrison, S. L. (2004), V region carbohydrate and antibody expression, J. Immunol. 172, 5489-5494.
186. Delorme, E.; Lorenzini,T.; Giffin, J.; Martin, F.; Jacobsen, F.; Boone,T.; Elliott, S. (1992), Role of glycosylation on the secretion and biological activity of erythropoietin, Biochemistry 31, 9871-9876.
187. Walsh, G.; Jefferis, R. (2006), Post-translational modifications in the context of therapeutic proteins, Nat. Biotechnol. 24, 1241-1252.
188. Stallforth, P.; Lepenies, B.; Adibekian, A.; Seeberger, P. H. (2009), Carbohydrates: A frontier in medicinal chemistry, J. Med. Chem. 52, 5561-5577.
189. Brooks, S. A. (2009), Strategies for analysis of the glycosylation of proteins: Current status and future perspectives, Molec. Biotechnol. 43, 76-88.
190. Beck, A.;Wagner-Rousset, E.; Bussat, M.-C.; Lokteff, M.; Klinguer-Hamour, C.; Haeuw, J.-F.; Goetsch, L.; Wurch, T.; van Dorsselaer, A.; CorvaÏa, N. (2008), Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fcfusion proteins, Curr. Pharm. Biotechnol. 9, 482-501.
191. Kamoda, S.; Kakehi, K. (2008), Evaluation of glycosylation for quality assurance of antibody pharmaceuticals by capillary electrophoresis, Electrophoresis 29, 3595-3604.
192. Ko, K.; Ahn, M.-H.; Song, M.; Choo, Y.-K.; Kim, H. S.; Ko, K.; Joung, H. (2008), Glycoengineering of biotherapeutic proteins in plants, Molec. Cells 25, 494-503.
193. Amon, S.; Zamfir, A. D.; Rizzi, A. (2008), Glycosylation analysis of glycoproteins and proteoglycans using capillary electrophoresis-mass spectrometry strategies, Electrophoresis 29, 2485-2507.
194. Budnik, B. A.; Lee, R. S.; Steen, J. A. J. (2006), Global methods for protein glycosylation analysis by mass spectrometry, Biochim. Biophys. Acta (Proteins Proteom.) 1764, 1870- 1880.
195. Morelle, W.; Canis, K.; Chirat, F.; Faid, V.; Michalski, J. C. (2006), The use of mass spectrometry for the proteomic analysis of glycosylation, Proteomics 6, 3993-4015.
196. Wuhrer,M.; Deelder,A. M.; Hokke, C. H. (2005), Protein glycosylation analysis by liquid chromatography-mass spectrometry, J. Chromatogr. B (Anal. Technol. Biomed. Life Sci.) 825, 124-133.
197. Harvey, D. J. (2005), Proteomic analysis of glycosylation: Structural determination of Nand O-linked glycans by mass spectrometry, Expert Rev. Proteom. 2, 87-101.
198. Amoresano, A.; Carpentieri, A.; Giangrande, C.; Palmese, A.; Chiappetta, G.; Marino, G.; Pucci, P. (2009), Technical advances in proteomics mass spectrometry: Identification of post-translational modifications, Clin. Chem. Lab. Med. 47, 647-665.
199. Sinha, S.; Pipes, G.; Topp, E. M.; Bondarenko, P. V.; Treuheit, M. J.; Gadgil, H. S. (2008), Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs, J. Am. Soc. Mass Spectrom. 19, 1643-1654.
200. Witze, E. S.; Old, W. M.; Resing, K. A.; Ahn, N. G. (2007), Mapping protein posttranslational modifications with mass spectrometry, Nat. Meth. 4, 798-806.
201. Su, X.; Ren, C.; Freitas, M. A. (2007), Mass spectrometry-based strategies for characterization of histones and their post-translational modifications, Expert Rev. Proteom. 4, 211-225.
202. Garcia, B. A.; Shabanowitz, J.; Hunt, D. F. (2007), Characterization of histones and their post-translational modifications by mass spectrometry, Curr. Opin. Chem. Biol. 11, 66-73.
203. Salzano, A. M.; Crescenzi, M. (2005), Mass spectrometry for protein identification and the study of post translational modifications, Ann. Istit. Super. Sanita 41, 443-450.
204. Jensen, O. N. (2004), Modification-specific proteomics: Characterization of post-translational modifications by mass spectrometry, Curr. Opin. Chem. Biol. 8, 33-41.
205. Kóster, B.; Mann, M. (1998), Identifying proteins and post-translational modifications by mass spectrometry, Curr. Opin. Struct. Biol. 8, 393-400.
206. Barnes, C. S.; Lim, A. (2007), Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals, Mass Spectrom. Rev. 26, 370-388.
207. Yuk, I. H. Y.;Wang, D. I. C. (2002), Changes in the overall extent of protein glycosylation by Chinese hamster ovary cells over the course of batch culture, Biotechnol. Appl. Biochem. 36, 133-140.
208. Bogosian, G.; Violand, B. N.; Dorward-King, E. J.;Workman,W. E.; Jung, P. E.; Kane, J. F. (1989), Biosynthesis and incorporation into protein of norleucine by Escherichia coli, J. Biol. Chem. 264, 531-539.
209. Eng, M.; Ling, V.; Briggs, J. A.; Souza, K.; Canova-Davis, E.; Powell, M. F.; De Young, L. R. (1997), Formulation development and primary degradation pathways for recombinant human nerve growth factor, Anal. Chem. 69, 4184-4190.
210. Geoghegan, K. F.; Dixon, H. B. F.; Rosner, P. J.; Hoth, L. R.; Lanzetti, A. J.; Borzilleri, K. A.; Marr, E. S.; Pezzullo, L. H.; Martin, L. B.; Lemotte, P. K.; McColl, A. S.; Kamath, A. V.; Stroh, J. G. (1999), Spontaneous a-N-6-phosphogluconoylation of a "His tag" in Escherichia coli: The cause of extra mass of 258 or 178 Da in fusion proteins, Anal. Biochem. 267, 169-184.
211. Du, P.; Loulakis, P.; Luo, C.; Mistry, A.; Simons, S. P.; LeMotte, P. K.; Rajamohan, F.; Rafidi, K.; Coleman, K. G.; Geoghegan, K. F.; Xie, Z. (2005), Phosphorylation of serine residues in histidine-tag sequences attached to recombinant protein kinases: A cause of heterogeneity inmass and complications in function, Protein Express. Purif. 44, 121-129.
212. Aon, J. C.; Caimi, R. J.; Taylor, A. H.; Lu, Q.; Oluboyede, F.; Dally, J.; Kessler, M. D.; Kerrigan, J. J.; Lewis, T. S.;Wysocki, L. A.; Patel, P. S. (2008), Suppressing posttranslational gluconoylation of heterologous proteins by metabolic engineering of Escherichia coli, Appl. Environ. Microbiol. 74, 950-958.
213. Ward, N. E.; Stewart, J. R.; Ioannides, C. G.; O'Brian, C. A. (2000), Oxidant-induced S-glutathiolation inactivates protein kinase C-a (PKC-a): A potential mechanism of PKC isozyme regulation, Biochemistry 39, 10319-10329.
214. Melchers, J.; Dirdjaja, N.; Ruppert, T.; Krauth-Siegel, R. L. (2007), Glutathionylation of trypanosomal thiol redox proteins, J. Biol. Chem. 282, 8678-8694.
215. Chu, F.; Ward, N. E.; O'Brian, C. A. (2003), PKC isozyme S-cysteinylation by cystine stimulates the pro-apoptotic isozyme PKCd and inactivates the oncogenic isozyme PKCe, Carcinogenesis 24, 317-325.
216. Fahey, R. C.; Brown, W. C.; Adams, W. B.; Worsham, M. B. (1978), Occurrence of glutathione in bacteria, J. Bacteriol. 133, 1126-1129.
217. McLaggan, D.; Logan, T. M.; Lynn, D. G.; Epstein,W. (1990), Involvement of g-glutamyl peptides in osmoadaptation of Escherichia coli, J. Bacteriol. 172, 3631-3636.
218. Gan-Schreier, H.; Okun, J. G.; Kohlmueller, D.; Langhans, C.-D.; Peters, V.; Ten Brink, H. J.; Verhoeven, N. M.; Jakobs, C.; Voelkl, A.; Hoffmann, G. F. (2005), Measurement of bile acid CoA esters by high-performance liquid chromatography-electrospray ionisation tandem mass spectrometry (HPLC-ESI-MS/MS), J. Mass Spectrom. 40, 882-889.
219. Liu, P.; Tarnowski, M. A.; O'Mara, B.W.;Wu, W.; Zhang, H.; Tamura, J. K.; Ackerman, M. S.; Tao, L.; Grace, M. J.; Russell, R. J. (2009), Rapid Commun. Mass Spectrom. 23, 3343-3349.